
Global Long Acting Beta Agonist Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Long Acting Beta Agonist market size will reach US$ million by 2031.
Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.
United States market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Long Acting Beta Agonist players cover Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Long Acting Beta Agonist Industry Forecast” looks at past sales and reviews total world Long Acting Beta Agonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Long Acting Beta Agonist sales for 2025 through 2031. With Long Acting Beta Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long Acting Beta Agonist industry.
This Insight Report provides a comprehensive analysis of the global Long Acting Beta Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long Acting Beta Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long Acting Beta Agonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long Acting Beta Agonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long Acting Beta Agonist.
This report presents a comprehensive overview, market shares, and growth opportunities of Long Acting Beta Agonist market by product type, application, key players and key regions and countries.
Segmentation by Type:
Liquid
Tablet
Segmentation by Application:
Hospitals
Clinics
Ambulatory Surgical Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sumitomo Dainippon Pharma
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim International
Mylan
Teva
Merck
Please note: The report will take approximately 2 business days to prepare and deliver.
Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.
United States market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Long Acting Beta Agonist players cover Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Long Acting Beta Agonist Industry Forecast” looks at past sales and reviews total world Long Acting Beta Agonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Long Acting Beta Agonist sales for 2025 through 2031. With Long Acting Beta Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long Acting Beta Agonist industry.
This Insight Report provides a comprehensive analysis of the global Long Acting Beta Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long Acting Beta Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long Acting Beta Agonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long Acting Beta Agonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long Acting Beta Agonist.
This report presents a comprehensive overview, market shares, and growth opportunities of Long Acting Beta Agonist market by product type, application, key players and key regions and countries.
Segmentation by Type:
Liquid
Tablet
Segmentation by Application:
Hospitals
Clinics
Ambulatory Surgical Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sumitomo Dainippon Pharma
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim International
Mylan
Teva
Merck
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
97 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.